

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
18 November 2021 (18.11.2021)



(10) International Publication Number
WO 2021/229302 A1

(51) International Patent Classification:

C07D 491/052 (2006.01) A61K 31/4743 (2006.01)
A61K 31/395 (2006.01) A61K 31/4745 (2006.01)
A61K 31/4741 (2006.01) A61P 31/20 (2006.01)

(21) International Application Number:

PCT/IB2021/000346

(22) International Filing Date:

13 May 2021 (13.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/024,559 14 May 2020 (14.05.2020) US

(71) Applicant: ARBUTUS BIOPHARMA CORPORATION [CA/CA]; 100-8900 Glenlyon Parkway, Burnaby, BC V5J 5J8 (CA).

(72) Inventors: COLE, Andrew G.; 65 Rocky Brook Road, Cranbury, NJ 08512 (US). DORSEY, Bruce D.; 1213 Meetinghouse Road, Ambler, PA 19002 (US). DUGAN, Benjamin J.; 437 Concord Road, Glen Mills, PA 19342 (US). FAN, Yi; 40 Bittersweet Drive, Doylestown, PA 18901 (US). KULTGEN, Steven G.; 1526 Russett Drive, Warminster, PA 18974 (US). MESAROS, Eugen F.; 113 Lombardy Road, Wallingford, PA 19086 (US). SOFIA, Michael J.; 3066 Antler Drive, Doylestown, PA 18902 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME



(57) Abstract: The present disclosure includes substituted tricyclic amides, or analogues thereof of formula (I) (I), wherein X, Y, ring A, R1, R5, R6 and R7 are as defined herein, and compositions comprising compounds of formula (I) that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.



WO 2021/229302 A1